244768-98-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 5-Methyl-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylate is used as a building block for the synthesis of various drug molecules. Its bicyclic structure and the protective nature of the tert-butyl group make it an ideal candidate for the development of new pharmaceuticals with enhanced biological activity.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Tert-Butyl 5-Methyl-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylate is employed as a valuable component for the design and synthesis of novel chemical compounds. Its unique structure and functional groups contribute to the exploration of new therapeutic agents and the improvement of existing ones.
Used in Chemical Reactions:
Tert-Butyl 5-Methyl-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylate is utilized as a protective group in chemical reactions, particularly in the synthesis of complex organic molecules. The tert-butyl group provides stability to the carboxylate functional group, allowing for better control over the reaction conditions and facilitating the synthesis of desired products.

Upstream product

• 61478-27-1 (2S,4S)-N-(tert-butoxycarbonyl)-4-(p-toluenesulfonyloxy)-2-<(p-toluenesulfonyloxy)methyl>pyrrolidine 
• 74-89-5 methylamine 
• 50-00-0 formaldehyd 
• 113451-59-5 (1S,4S)-2,5-Diaza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 

Downstream Products

• 52321-26-3 (1S,4S)-5-methyl-2,5-diazabicyclo<2.2.1>heptane dihydrochloride 

Relevant academic research and scientific papers

Inhibitors of Bruton's Tyrosine Kinase

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Azabicyclic sulfonamides as potent 11β-HSD1 inhibitors

Inhibition of 11β-HSD1 has demonstrated potential in the treatment of various components of metabolic syndrome. We wish to report herein the discovery of novel azabicyclic sulfonamide based 11β-HSD1 inhibitors. Highly potent compounds exhibiting inhibitor

SUBSTITUTED BICYCLIC PIPERIDINYL-AND PIPERAZINYL- SULFONAMIDES USEFUL TO INHIBIT 11β-HYDROXYSTEROID DEHYDROGENASE TYPE-1

In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.

Synthesis of substituted 2,5-diazabicyclo[2.2.1]heptanes

A new method is proposed for the synthesis of substituted 2,5-diazabicyclo[2.2.1]heptanes from 1-(tertbutoxycarbonyl)-4-tosyloxy-2-(tosyloxymethyl)pyrrolidine. 1H NMR spectroscopy indicated multiple conformations of 2-(tert-butoxycarbonyl)-2,5-